Tumor necrosis factor α neutralization seems a rational therapy for myositis because this proinflammatory cytokine has been implicated in the pathogenesis of this disorder. Until now, we have treated 2 patients with a chimeric anti-TNF-α monoclonal antibody (infliximab). Both patients demonstrated a marked and sustained subjective and objective improvement without the occurrence of any side effects. These preliminary results suggest that anti-TNF-α treatment with infliximab is a safe and rapidly effective therapy for myositis.

Keywords:
Myositis, Dermatomyositis, Polymyositis, Tumor necrosis factor
1.
Dalakas MC: Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991;325:1487–1498.
2.
Amato AA, Barohn RJ: Idiopathic inflammatory myopathies. Neurol Clin 1997;15:615–648.
3.
Catoggio LJ: Inflammatory muscle disease: Management; in Klippel JH, Dieppe PA (ed): Rheumatology. London, Mosby, 1998, pp 7.15.1–7.15.6.
4.
Lindberg C, Oldfors A, Tarkowski A: Local T-cell proliferation and differentiation in inflammatory myopathies. Scand J Immunol 1995;41:421–426.
5.
Lundberg I, Brengman JM, Engel AG: Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995;63:9–16.
6.
Tews DS, Goebel HH: Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996;55:342–347.
7.
Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L: Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:865–874.
8.
Lundberg IE, Nyberg P: New developments in the role of cytokines and chemokines in inflammatory myopathies. Curr Opin Rheumatol 1998;10:521–529.
9.
De Bleecker J, Meire V, Declercq W, Van Aken E: Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999;9:239–246.
10.
Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA Jr, O’Connor JV: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986;136:1433–1450.
11.
Keystone EC: The role of tumor necrosis factor antagonism in clinical practice. J Rheumatol 1999;26(suppl 57):22–28.
12.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552–1563.
13.
Moreland LW: Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 1999;26(suppl 57):7–15.
14.
Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119–133.
15.
Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344–347.
16.
Van Crevel R, Van der Ven-Jongekrijg J, Netea MG, De Lange W, Kullberg WJ, Van der Meer JW: Disease-specific ex vivo stimulation of whole blood for cytokine production: Applications in the study of tuberculosis. J Immunol Methods 1999;222:145–153.
17.
Drenth JP, Van Uum SH, Van Deuren M, Pesman GJ, Van der Ven-Jongekrijg J, Van der Meer JW: Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1beta production. J Appl Physiol 1995;79:1497–1503.
18.
Personius KE, Pandya S, King WM, Tawil R, McDermott MP: Facioscapulohumeral dystrophy natural history study: Standardization of testing procedures and reliability of measurements. The FSHDY group. Phys Ther 1994;74:253–263.
19.
The national isometric muscle strength (NIMS) database consortium: Muscular weakness assessment: Use of normal isometric strength data. Arch Phys Med Rehabil 1996;77:1251–1255.
20.
Lundberg I, Kratz AK, Alexanderson H, Patarroyo M: Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000;43:336–348.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.